2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2015

9:00AM-11:00AM: Abstract Number: 569

Neurophil to Lymphocyte Ratio Is a Reliable Marker of Treatment Response in Rheumatoid Arthritis Patients during Tocilizumab Therapy

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I

9:00AM-11:00AM: Abstract Number: 208

Neutrophil-Mediated Mechanisms of Drug-Induced Autoimmunity

Innate Immunity and Rheumatic Disease Poster I

9:00AM-11:00AM: Abstract Number: 860

Neutrophil/Lymphocyte Ratio: Could It be a Prognostic Indicator for Renal Outcome in Patients with Granulomatosis with Polyangiitis?

Vasculitis Poster I

9:00AM-11:00AM: Abstract Number: 101

New Technologies for Typing Self-Identifying Antigens Encoded By HLA Genes Provide Cost-Effective Alternatives to Identifying B27 Allele Status in Rheumatoid Arthritis Subjects

Genetics, Genomics and Proteomics Poster I

9:00AM-11:00AM: Abstract Number: 371

New Vertebral Fractures after Vertebroplasty: Two Year Results from a Randomised Placebo-Controlled Trial

Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 94

NGS Panel for the Detection of Monogenic SLE in Children: Initial Results

Genetics, Genomics and Proteomics Poster I

9:00AM-11:00AM: Abstract Number: 848

Nitroglycerin Patch Application in Systemic Sclerosis: Evaluation By Laser Doppler Imaging

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster I

9:00AM-11:00AM: Abstract Number: 454

No Sex Bias in the Escalation of Therapy in the Treatment of Early Inflammatory Arthritis

Rheumatoid Arthritis - Clinical Aspects Poster I

9:00AM-11:00AM: Abstract Number: 64

Nociceptive Flexion Reflex Threshold: Possible Surrogate Marker of Symptom Severity in Fibromyalgia

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster I

9:00AM-11:00AM: Abstract Number: 498

Non-Adherence to Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: An Italian Survey

Rheumatoid Arthritis - Clinical Aspects Poster I

9:00AM-11:00AM: Abstract Number: 839

Occupational Exposures in Patients with Systemic Sclerosis Associated with Increased Frequency of Interstitial Lung Disease and Primary Pulmonary Hypertension

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster I

9:00AM-11:00AM: Abstract Number: 500

Ofatumumab for Rheumatoid Arthritis: A Cochrane Systematic Review and Meta-Analysis

Rheumatoid Arthritis - Clinical Aspects Poster I

9:00AM-11:00AM: Abstract Number: 326

Older Adults without Extreme Obesity Are at Highest Risk for Accelerated Knee Osteoarthritis

Osteoarthritis - Clinical Aspects Poster I: Treatments and Metabolic Risk Factors

9:00AM-11:00AM: Abstract Number: 554

On Drug and Drug-Free Remission By Baseline Disease Duration: Abatacept Versus Methotrexate Comparison in Patients with Early Rheumatoid Arthritis

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I

9:00AM-11:00AM: Abstract Number: 477

On-Demand Use of Etanercept Only for Disease Flares Reduced the Disease Activity Score and Structural Damage Equivalent to Fully-Use of Etanercept in RA Patients

Rheumatoid Arthritis - Clinical Aspects Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].